A 23-year-old woman presented with trigeminal neuralgia four months after hematopoietic stem cell transplantation (HSCT) for acute myeloblastic leukemia. No leukemic cells were found in the cerebrospinal fluid. Initial brain magnetic resonance imaging (MRI) did not reveal any abnormality. After symptom exacerbation with diplopia, second MRI showed an irregular mass at the right petrous apex, with uniform enhancement and a clear margin which was interpreted as a meningioma. The pathology and immunohistochemistry finally confirmed the diagnosis of granulocytic sarcoma. This case suggests that granulocytic sarcoma should be remembered as a very rare and a malignant pathology in the differential diagnosis of neurologic complications following HSCT.
Introduction
Relapse of the original disease remains one of the most important causes of failure after allogeneic hematopoietic stem cell transplantation (HSCT) for leukemia. Although the majority of patients develop systemic relapse, extramedullary relapse has been also observed after HSCT. As a localized extramedullary relapse of acute myeloblastic leukemia (AML), granulocytic sarcoma is a rare neurological complication after allogeneic HSCT (1) . In this report, we describe a young patient with trigeminal neuralgia and diplopia caused by intracerebral granulocytic sarcoma.
Case Report
A 23-year-old woman was referred to the neurology department with right facial numbness and pain. She was originally examined because of a fever one year previously and was diagnosed as having acute myeloblastic leukemia M2b (AML-M2b). The cranial MRI and cerebral spinal fluid (CSF) study were normal. Three cycles of chemotherapy were achieved with rubomycin, cytarabine. Four months previously, she underwent allogenic HSCT and complete remission was confirmed by a bone marrow study. On neurological examination, pinprick sensation was decreased in the V2 and V3 dermatomes of the right side of her face. Slight weakness of the right masseter was detected. Lumbar puncture revealed a normal opening pressure, glucose, protein, cell count, and cytology. After symptomatic treatment, the symptoms did not resolve and she complained of diplopia three weeks later. Neuro-ophthalmologic examination showed marked limitation of abduction of the right eye. The result of repeated lumbar puncture was normal. Bone marrow aspiration demonstrated that the leukemia was in remission. Brain MRI revealed an irregular mass in the right middle cranial fossa that caused abutting and deforming of the temporal lobe and pons. The lesion was isointense to brain on T1-weighted and T2-weighted images with a clear margin and uniform contrast enhancement, which was interpreted as a meningioma by neuroradiologist ( Fig. 1A and B ).There were no findings of destruction of the petrous bone.
She was then transferred to neurosurgical department and underwent surgery. The mass was removed with a green appearance which involved dura and did not invade adjacent parenchyma. Histopathological examination revealed the tumor was composed of mononuclear cells (Fig. 2) . The immunohistochemical studies yielded the expression of myeloperoxidase (Fig. 3) , CD43, CD79, CD117(c-Kit), leukocyte common antigen, but not of B cell-specific (CD20) or T cell-specific antigens (CD3). The final pathological diagnosis was granulocytic sarcoma. After receiving radiation combined with intrathecal chemotherapy, her symptoms were alleviated.
Discussion
HSCT has been used increasingly to treat various hematologic malignancies and solid tumors. Since the gradual decline of other complications after modifications of therapeutic protocols and systematic prophylaxis, severe neurologic complications now seem to be a major problem after HSCT. The majority of patients after HSCT develop bone marrow relapse, although CNS relapse presenting as extramedullary relapse has been reported to be one of the neurologic complications after HPCT (2) .
Intracranial granulocytic sarcoma presenting as CNS relapse after HSCT is a rare entity. Granulocytic sarcoma, also termed "chloroma" for the green color, is an extramedullary solid tumor composed of immature myeloid cells or myeloblasts and it can occur in leukemia, myeloproliferative and myelodysplastic disorders (3) . It can occur anywhere in the body and at any age, involving bone, periostium, lymph nodes, skin, breast, ovary, rectum, pancreas, urinary bladder, or the central nervous system (4). The neurologic symptoms vary according to the location of the tumor, mainly due to the mass effect (5).
The exact pathogenesis of granulocytic sarcoma is still unclear and it may be the first sign of relapse after bone marrow transplantation or may precede the onset of systemic disease (6, 7) . Central nervous system (CNS) leukemia is believed to develop as a result of hematogenous spread or direct extension from involved cranial bone marrow. Leukemic cells may pass from the bone marrow of the skull to the dura and then to the subarachnoid space and the VirchowRobin spaces resulting in invasion of the brain surface (8) . This involvement is usually meningeal and leukemic cells infiltrate the dura, the leptomeninges or both, and may be diffuse or focal. Although the HSCT is applied systemically, it may not be sufficient to affect the CNS because of a certain barrier such as blood brain barrier. This limitation could later lead to the proliferation of intracranial tumor cells which metastasized before HSCT (9) . However, the present case had a normal cerebral spinal fluid study and leukemic mass without parenchymal involvement was observed. We could not exclude the possibility that leukemic cells pass from the bone marrow of the skull to the dura.
Granulocytic sarcoma requires an early diagnosis because a focal relapse could eventually be cured by local therapy (e.g., radiation) (10). Diagnosis, however, proves to be challenging because clinical and laboratory data are frequently not indicative. On initial CT, intracranial granulocytic sarcoma may appear as a hyperdense mass and slightly hypointense to isointense on both T1-weighted and T2-weighted images, with homogeneous enhancement after contrast on brain MRI (11, 12) . It could present as a dural-based mass with typical dual tail sign. These imaging features may mimic meningioma just as in the present patient. The past history, rapid growth, careful evaluation of morphology and immunohistochemistry of the tumor is therefore very helpful in this diagnosis.
The young woman in this case first came to the outpatient department with trigeminal neuralgia. Based on the negative results of brain MRI, leptomeningeal involvement by leukemia was considered while we did not find the presence of leukemic cells in the CSF. Only when the abducens nerve was involved and upon reexamination of brain MRI with enhancement did we find the mass. We suspected that trigeminal neuralgia was caused by the compression of the granulocytic sarcoma and the lesion may be so small that it could easily be overlooked on the initial routine brain MRI.
The management of granulocytic sarcoma depends on the size and location of the tumors. Since granulocytic sarcoma is sensitive to local irradiation, radiation therapy is preferred. But there are no guidelines about the radiation combined with chemotherapy treatment in this situation. Surgical resection, irradiation and chemotherapy may help control the progression, but the effectiveness remains controversial (13) .
In conclusion, granulocytic sarcoma should be remembered as a very rare and malignant pathology in the differential diagnosis of neurologic complications following HSCT. The use of an appropriate imaging protocol such as cranial MRI with enhancement is important in the early detection of the tumor.
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